PT2119452T - Composição farmacêutica que compreende um anticorpo monoclonal anti-cd6 utilizado no diagnóstico e tratamento de artrite reumatoide - Google Patents

Composição farmacêutica que compreende um anticorpo monoclonal anti-cd6 utilizado no diagnóstico e tratamento de artrite reumatoide

Info

Publication number
PT2119452T
PT2119452T PT78559838T PT07855983T PT2119452T PT 2119452 T PT2119452 T PT 2119452T PT 78559838 T PT78559838 T PT 78559838T PT 07855983 T PT07855983 T PT 07855983T PT 2119452 T PT2119452 T PT 2119452T
Authority
PT
Portugal
Prior art keywords
diagnosis
treatment
pharmaceutical composition
monoclonal antibody
rheumatoid arthritis
Prior art date
Application number
PT78559838T
Other languages
English (en)
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Publication of PT2119452T publication Critical patent/PT2119452T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT78559838T 2006-12-26 2007-12-24 Composição farmacêutica que compreende um anticorpo monoclonal anti-cd6 utilizado no diagnóstico e tratamento de artrite reumatoide PT2119452T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060250 2006-12-26

Publications (1)

Publication Number Publication Date
PT2119452T true PT2119452T (pt) 2020-05-08

Family

ID=39562112

Family Applications (1)

Application Number Title Priority Date Filing Date
PT78559838T PT2119452T (pt) 2006-12-26 2007-12-24 Composição farmacêutica que compreende um anticorpo monoclonal anti-cd6 utilizado no diagnóstico e tratamento de artrite reumatoide

Country Status (19)

Country Link
US (3) US20100092423A1 (pt)
EP (1) EP2119452B1 (pt)
KR (1) KR101482956B1 (pt)
CN (2) CN101657215A (pt)
AR (1) AR064527A1 (pt)
AU (1) AU2007336563B2 (pt)
CA (1) CA2676185C (pt)
DK (1) DK2119452T3 (pt)
ES (1) ES2785043T3 (pt)
HK (1) HK1213782A1 (pt)
IT (1) ITTO20070942A1 (pt)
MY (1) MY165625A (pt)
NZ (1) NZ578635A (pt)
PE (1) PE20081553A1 (pt)
PL (1) PL2119452T3 (pt)
PT (1) PT2119452T (pt)
RU (1) RU2472526C2 (pt)
UY (1) UY30838A1 (pt)
WO (1) WO2008077355A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716919C (en) * 2008-03-14 2015-01-20 Biocon Limited An anti-cd6 monoclonal antibody and use thereof
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
US11037196B2 (en) 2012-02-24 2021-06-15 Netclearance Systems, Inc. Interactive advertising using proximity events
US11062258B2 (en) 2012-02-24 2021-07-13 Netclearance Systems, Inc. Automated logistics management using proximity events
PT3024485T (pt) 2013-07-23 2021-01-25 Biocon Ltd Utilização de um parceiro de ligação de cd6 e método baseado no mesmo
DK3269735T3 (da) * 2015-03-13 2020-12-14 Jiangsu Hengrui Medicine Co Antistof mod sclerostin, antigenbindende fragment og medicinsk anvendelse deraf
SG11201806696WA (en) * 2016-02-10 2018-09-27 Cayman Chemical Co Inc Anti-citrullinated hla polypeptide antibodies and uses thereof
EP3529274B1 (en) 2016-10-21 2024-04-17 Biocon Limited A monoclonal antibody and a method of use for the treatment of lupus
US11151534B2 (en) * 2016-11-29 2021-10-19 Netclearance Systems, Inc. Consumer interaction module for point-of-sale (POS) systems
US11334889B2 (en) 2016-11-29 2022-05-17 Netclearance Systems, Inc. Mobile ticketing based on proximity
CN109903854B (zh) * 2019-01-25 2023-04-07 电子科技大学 一种基于中医药文献的核心药物识别方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US699755A (en) 1902-03-06 1902-05-13 Ira G Hoag Train-order box in connection with semaphores.
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0631783A1 (en) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
WO1995012614A1 (en) * 1993-11-02 1995-05-11 Duke University Cd6 ligand
US5423562A (en) * 1993-11-05 1995-06-13 Pearce, Jr.; Fredric C. Chair lift
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
SK282894B6 (sk) * 1996-03-20 2003-01-09 Hoechst Marion Roussel Tricyklické zlúčeniny, spôsob ich prípravy a medziprodukty tohto spôsobu, ich použitie ako liečiv a farmaceutické zmesi, ktoré ich obsahujú
WO1998043089A1 (en) * 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
MXPA01011279A (es) * 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
FI110553B (fi) * 2001-02-12 2003-02-14 Perlos Oyj Liitin ja liittimen irtopala
ES2192128B1 (es) * 2001-04-27 2005-01-01 Universidad De Vigo Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
CN101031305A (zh) * 2004-09-29 2007-09-05 兴和株式会社 类风湿性关节炎的预防和/或治疗药物
EP2845865A1 (en) * 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
ES2359567T3 (es) * 2004-12-29 2011-05-24 Yuhan Corporation Anticuerpo humanizado específico para el factor de necrosis tumoral-alfa.

Also Published As

Publication number Publication date
WO2008077355A1 (es) 2008-07-03
HK1213782A1 (zh) 2016-07-15
KR20090122910A (ko) 2009-12-01
US20160024220A1 (en) 2016-01-28
US20100092423A1 (en) 2010-04-15
EP2119452B1 (en) 2020-03-04
CN105251004A (zh) 2016-01-20
PL2119452T3 (pl) 2021-03-08
CN101657215A (zh) 2010-02-24
EP2119452A4 (en) 2012-06-06
CA2676185A1 (en) 2008-07-03
CA2676185C (en) 2013-03-12
US20170066835A1 (en) 2017-03-09
PE20081553A1 (es) 2008-12-10
MY165625A (en) 2018-04-18
KR101482956B1 (ko) 2015-01-15
EP2119452A1 (en) 2009-11-18
AU2007336563B2 (en) 2012-11-01
NZ578635A (en) 2012-03-30
RU2472526C2 (ru) 2013-01-20
ES2785043T3 (es) 2020-10-05
UY30838A1 (es) 2008-07-31
AR064527A1 (es) 2009-04-08
RU2009128659A (ru) 2011-02-10
AU2007336563A1 (en) 2008-07-03
ITTO20070942A1 (it) 2008-06-27
DK2119452T3 (da) 2020-04-20

Similar Documents

Publication Publication Date Title
HK1213782A1 (zh) 在診斷和治療類風濕性關節炎中使用的包含抗- 單克隆抗體的藥物組合物
IL254157B (en) 3–14–eta antibodies and their uses for the diagnosis and treatment of arthritis
EP2103628A4 (en) MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY
IL212633A (en) A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs
PL1765314T3 (pl) Zestaw składników farmaceutycznych do leczenia choroby i objawów reumatoidalnego zapalenia stawów
IL199216A (en) Monoclonal Antibodies Against 3angptl, Pharmaceuticals Containing Them and Their Uses
IL196550A0 (en) Anti-il-6 monoclonal antibodies and uses thereof
ZA200902256B (en) Human antibodies that bind cxcr4 and uses thereof
IL219268A (en) Anti-b79cd antibody, immunosuppressant and pharmacological agent that includes and uses it
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
IL214779A (en) Isolated monoclonal antibody or epitope-binding antibody on cadm1, methods of preparation and use for drug preparation
EP1940466A4 (en) ANTI-ADDL MONOCLONAL ANTIBODIES AND THEIR USE
IL197148A (en) Antibodies and preparations for the treatment of antibodies caused by antibodies
EP1978034A4 (en) ANTI-PERIOSTINE ANTIBODIES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PERIOSTIN-RELATED DISEASE CONTAINING THE ANTIBODY
HUS1800034I1 (hu) Anti-FGF23 ellenanyag és anti-FGF23 ellenanyagot tartalmazó gyógyászati készítmény
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
EP2048162A4 (en) NEW MONOCLONAL ANTIBODY AND ITS USE
EP2077325A4 (en) MONOCLONAL ANTIBODY AND ITS USE
IL211904A (en) Kit and preparations containing methotrexate and anti-cd4 antibody for the treatment of rheumatic disease
HK1115598A1 (en) Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
WO2007103468A3 (en) Use of vx-702 for treating rheumatoid arthritis
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
TH0701006712B (th) องค์ประกอบทางเภสัชกรรมซึ่งประกอบรวมด้วยแอนตี้-cd6 โมโนโคลนอลแอนติบอดีที่มีประโยชน์สำหรับการวินิจฉัยและรักษาข้ออักเสบรูมาตอยด์
ZA200800047B (en) Humanised antibodies specific for NOGO-A and pharmaceutical uses thereof